Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of a New Goserelin Acetate 10.8 mg Depot Formulation in Prostate Cancer
NCT04060043Phase 1Completed
- Sponsor
- CMX Research
- Start
- Feb 2017
- Primary completion
- Dec 2017
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of goserelin in prostate cancer (PCa), sponsored by CMX Research. Primary endpoint: Changes in testosterone at 84 days. Started Feb 2017; status: completed.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04060043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060043.